0000899243-20-002488.txt : 20200131
0000899243-20-002488.hdr.sgml : 20200131
20200131185034
ACCESSION NUMBER: 0000899243-20-002488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200131
FILED AS OF DATE: 20200131
DATE AS OF CHANGE: 20200131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUEHL DANIEL W
CENTRAL INDEX KEY: 0001283569
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 20566505
MAIL ADDRESS:
STREET 1: 5 BILLERICA PARK
STREET 2: 101 BILLERICA AVE
CITY: NORTH BILLERCA
STATE: MA
ZIP: 01862
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-31
0
0001466301
Clovis Oncology, Inc.
CLVS
0001283569
MUEHL DANIEL W
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Restricted Stock Units
2020-01-31
4
A
0
74000
0.00
A
Common Stock
74000
74000
D
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
The Restricted Stock Units shall vest as to 25% of the units on February 1, 2021, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer
/s/ Daniel W. Muehl
2020-01-31